Fairview Capital Investment Management LLC Cuts Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Fairview Capital Investment Management LLC lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 80.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,063 shares of the medical equipment provider’s stock after selling 28,779 shares during the period. Fairview Capital Investment Management LLC’s holdings in Zimmer Biomet were worth $746,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ZBH. B. Riley Wealth Advisors Inc. lifted its stake in Zimmer Biomet by 17.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider’s stock worth $260,000 after purchasing an additional 358 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Zimmer Biomet by 3.9% in the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock valued at $1,732,000 after purchasing an additional 609 shares in the last quarter. First Hawaiian Bank raised its stake in shares of Zimmer Biomet by 14.0% in the fourth quarter. First Hawaiian Bank now owns 20,400 shares of the medical equipment provider’s stock valued at $2,155,000 after acquiring an additional 2,500 shares in the last quarter. ORG Partners LLC boosted its stake in shares of Zimmer Biomet by 14,497.5% in the 4th quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider’s stock valued at $617,000 after buying an additional 5,799 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Zimmer Biomet by 8.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 15,845 shares of the medical equipment provider’s stock worth $1,710,000 after acquiring an additional 1,173 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZBH. JMP Securities cut their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a report on Wednesday. Raymond James dropped their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating on the stock in a research note on Tuesday. Royal Bank of Canada decreased their price target on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research note on Tuesday. Wells Fargo & Company reduced their price target on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research report on Tuesday. Finally, Barclays cut their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $114.15.

Zimmer Biomet Trading Up 1.0 %

ZBH stock opened at $95.07 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $122.25. The company has a market cap of $18.81 billion, a P/E ratio of 21.36, a PEG ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The business has a fifty day moving average of $104.61 and a 200-day moving average of $106.17.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.94 earnings per share. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.